Differences in fatty acid metabolic disorder between ischemic myocardium and doxorubicin-induced myocardial damage: Assessment using BMIPP dynamic SPECT with analysis by the Rutland method

Journal of Nuclear Medicine

Volumn 43, Issue 10, 2002, Pages 1286-1294

  Kitagawa, Kakuya ^a   Takeda, Kan ^a   Saito, Kimimasa ^a   Okamoto, Shinya ^a   Makino, Katsutoshi ^a   Maeda, Hisato ^a   Ichihara, Takashi ^a  

^a Matsusaka Central Hospital   (Japan)

Author keywords

BMIPP; Doxorubicin induced myocardial damage; Dynamic SPECT; Ischemic heart disease; Rutland analysis

Indexed keywords

15 (4 IODOPHENYL) 3 METHYLPENTADECANOIC ACID I 123; DOXORUBICIN; FATTY ACID;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CALCULATION; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG METABOLISM; FATTY ACID METABOLISM; FEMALE; HUMAN; IMAGE ANALYSIS; ISCHEMIC HEART DISEASE; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; RUTLAND ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL ANALYSIS;

AGED; ANTINEOPLASTIC AGENTS; CARDIOMYOPATHIES; DOXORUBICIN; FATTY ACIDS; FEMALE; HEART; HUMANS; IODINE RADIOISOTOPES; IODOBENZENES; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0036788496     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Neely JR, Rovetto MJ, Oram JF. Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis. 1972;15:685-698.
2. Knapp FF, Ambrose KR, Goodman MM. New radioiodinated methyl-branched fatty acids for cardiac studies. Eur J Nucl Med. 1986;12(suppl):S39-S44.
3. Knapp FF, Kropp J. Goodman MM, et al. The development of iodine-123-methyl-branched fatty acids and their applications in nuclear cardiology. Ann Nucl Med. 1993;7: SSII-1-SII-14.
4. Nakata T, Hashimoto A. Kobayashi H. et al. Outcome significance of thallium-201 and iodine-123 BMIPP perfusion-metabolism mismatch in preinfarction angina. J Nucl Med. 1998;39:1492-1499.
5. 1231l-BMIPP in a canine model with ischemia: implications of perfusion-metabolism mismatch on SPECT images in patients with ischemic heart disease. J Nucl Med. 1999;40:471-478.
6. Hosokawa R, Nohara R, Okuda K. et al. Cardiac metabolism of 1-123-β-methyl-p-iodophenyl pentadecanoic acid (I-123 BMIPP) in normal dogs and those pretreated with camitine palmitoyltranseferase I inhibitor (etomoxir): contribution of α- and β-oxidation [abstract]. J Nucl Med. 1995;36(suppl):137P.
7. Fujibayashi Y, Yonekura Y, Takemura Y, et al. Myocardial accumulation of iodinated beta-methyl-branched fatty acid analogue, iodine-125-15-(p-iodophenyl)-3-(R,S)methylpentadecanoic acid (BMIPP), in relation to ATP concentration. J Nucl Med. 1990;31:1818-1822.
8. Saito K, Takeda K, Okamoto S, et al. Detection of doxorubicin cardiotoxicity by using iodine-123 BMIPP early dynamic SPECT: quantitative evaluation of early abnormality of fatty acid metabolism with the Rutland method. J Nucl Cardiol. 2000;7:553-561.
9. Ichihara T, Ogawa K, Motomura N, Kubo A, Hashimoto S. Compton scatter compensation using the triple-energy window method for single- and dualisotope SPECT. J Nucl Med. 1993;34:2216-2221.
10. 131I-hippuran renograms. Br J Radiol. 1979:52:134-137.
11. Knapp FF. Myocardial metabolism of radioiodinated BMIPP. J Nucl Med. 1995;36:1051-1054.
12. Hwang EH, Taki J, Yasue S, et al. Absent myocardial iodine-123-BMIPP uptake and platelet/monocyte CD36 deficiency. J Nucl Med. 1998;39:1681-1684.
13. Yamamichi Y, Kusuoka H, Morishita K, et al. Metabolism of iodine-123-BMIPP in perfused rat hearts. J Nucl Med. 1995;36:1043-1050.
14. Fujibayashi Y, Nohara R, Hosokawa R, et al. Metabolism and kinetics of iodine-123-BMIPP in canine myocardium. J Nucl Med. 1996;37:757-761.
15. 123I-BMIPP). Eur J Nucl Med. 1996;23:383-389.
16. Nohara R, Okuda K, Ogino M, et al. Evaluation of myocardial viability with iodine-123-BMIPP in a canine model. J Nucl Med. 1996;37:1403-1407.
17. Takeda K, Saito K, Makino K. et al. Iodine-123-BMIPP myocardial washout and cardiac work during exercise in normal and ischemic hearts. J Nucl Med. 1997;38:559-563.
18. Matsunari I, Saga T, Taki J, et al. Kinetics of iodine-123-BMIPP in patients with prior myocardial infarction: assessment with dynamic rest and stress thallium-201 SPECT. J Nucl Med. 1994;35:1279-1285.
19. Makino K, Okamoto R, Saito K, et al. Simple diagnostic procedure in patient with ischemic heart disease: assessment with dynamic iodine-123 BMIPP SPECT compared with stress thallium-201 SPECT [abstract]. J Nucl Med. 1997;38(suppl):165P-166P.
20. Kobayashi H, Kusakabe K, Momose M, et al. Evaluation of myocardial perfusion and fatty acid uptake using a single injection of iodine-123-BMIPP in patients with acute coronary syndromes. J Nucl Med. 1998;39:1117-1122.
21. Hosokawa R, Nohara R, Fujibayashi Y. et al. Myocardial kinetics of iodine-123-BMIPP in canine myocardium after regional ischemia and reperfusion: implications for clinical SPECT. J Nucl Med. 1997;38:1857-1863.
22. Olson RD, Mushlin PS, Brenner DE, et al. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA. 1988;85:3585-3589.
23. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978;62:865-872.
24. Goormaghtigh E, Pollakis G, Ruysschaert JM. Mitochondrial membrane modifications induced by adriamycin-mediated electron transport, Biochem Pharmacol. 1982;32:889-893.
25. Erland JFD, Poul KJ. Destruction of phospholipids and respiratory-chain activity in pig-heart submitochondrial particles induced by an adriamycin-iron complex. Eur J Biochem. 1983;132:551-556.
26. Seraydarian MW, Artaza L. Modification by adenosine of the effect of adriamycin on myocardial cells in culture. Cancer Res. 1979;39:2940-2944.
27. Neri B, Cini-Neri G, D'Alterio M. Effect of anthracyclines and ATP intracellular concentration in rat heart slices. Biochem Biophys Res. 1984;125:954-960.
28. Kataoka K, Nohara R, Hosokawa R, et al. Myocardial lipid metabolism in compensated and advanced stages of heart failure: evaluation by canine pacing model with BMIPP. J Nucl Med. 2001;42:124-129.